Anti-ROR1 antibodies
US11845793B2 · kind B2 · utility
0Cited by
16References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 31, 2016 |
| Grant date | Dec 19, 2023 |
| Priority date | — |
| Expiry date | Mar 9, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/61
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a human or humanized antibody, or an antibody-based binding protein, modified antibody format retaining target binding capacity, antibody derivative or fragment retaining target binding capacity, which targets Receptor tyrosine kinase-like orphan receptor-1 (ROR1). It further relates to bi- or multispecific antibodies, to Immunoligand-Drug Conjugates, to Chimeric Antigen Receptors and to T-cells comprising such Chimeric Antigen Receptors.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.